Genetic Causes of Cerebral Palsy
5 sections · 25 min
Redefining Cerebral Palsy: Beyond Perinatal Injury
Cerebral palsy (CP) is clinically defined as a group of permanent disorders of movement and posture caused by non-progressive disturbances that occurred in the developing fetal or infant brain. Historically, CP was considered synonymous with perinatal hypoxic-ischemic injury. However, large epidemiological and genomic studies now demonstrate that genetic causes — including chromosomal abnormalities, pathogenic copy number variants, and single-gene disorders — account for approximately 20–30% of CP cases, and potentially more in cases without a clear perinatal etiology.
CP Motor Subtypes
| Subtype | Motor Topography | Predominant Tone | MRI Correlates |
|---|---|---|---|
| Spastic (~80%) | Diplegia / hemiplegia / quadriplegia | Velocity-dependent ↑ tone | PVL (preterm diplegia); MCA infarct (hemiplegia); diffuse injury (quad) |
| Dyskinetic (~15%) | Trunk / limb / whole-body | Dystonia ± choreoathetosis | Bilateral BG/thalamic signal (term HIE); kernicterus → GP |
| Ataxic (~5%) | Trunk / appendicular | Cerebellar ataxia / hypotonia | Cerebellar hypoplasia; posterior fossa malformation |
| Mixed | Variable | Spasticity + dystonia most common | Reflects mixed mechanisms |
GMFCS Levels I–V
| Level | Functional Description | Mobility |
|---|---|---|
| I | Walks without limitations | Community ambulation; runs/jumps with speed & coordination limitations |
| II | Walks with limitations | Assistive device outdoors; limited stairs & uneven surfaces |
| III | Walks with hand-held device | Wheelchair for distances; some household ambulation |
| IV | Wheelchair-dependent | May achieve standing transfers; limited self-mobility |
| V | Transported in wheelchair | No independent mobility; head/trunk control limited |
Clinical Pearl: GMFCS level is the strongest predictor of long-term ambulation. Genetic diagnosis does not change GMFCS but may redirect treatment strategy (e.g., DRD → levodopa instead of SDR).
Key Points
- Modern definition: CP is a clinical syndrome (motor impairment + non-progressive brain abnormality) — not a specific diagnosis; etiology must be sought
- Genetic contribution: ~14–31% of 'idiopathic' CP cases have identifiable genetic cause by chromosomal microarray + exome sequencing; genetic cause more common in term births without perinatal risk factors
- CP mimics (treatable conditions misdiagnosed as CP): dopa-responsive dystonia (DYT-GCH1; see [[dystonia|Genetic Dystonias]] module), GLUT1 deficiency, AADC deficiency (DDC), glutaric aciduria type 1, biotinidase deficiency, arginase deficiency (ARG1) — critical to exclude before accepting CP label
- Brain imaging in CP: MRI normal in 15–30% — higher genetic yield in these cases; periventricular leukomalacia (preterm injury), cortical dysplasia (genetic), vascular patterns (coagulopathy, COL4A1) all provide diagnostic clues
- Clinical subtypes and genetic associations: spastic diplegia (periventricular leukomalacia most common — but also SPAST, PLP1 spastic paraplegia), dystonic CP (often treatable, DRD must be excluded), hemiplegic CP (focal cortical malformation, stroke, COL4A1)
✦ Check Your Understanding
A 4-year-old child born at term without perinatal complications has been labeled with 'spastic diplegic cerebral palsy.' MRI is reported as normal. She has diurnal fluctuation of her tone — worse in the evening, better in the morning. The most important next step is:
Select an answer to reveal the explanation
Chromosomal Abnormalities and CNVs in CP
Chromosomal abnormalities and copy number variants (CNVs) are identified in 8–15% of children with CP phenotype. These include classic chromosomal aneuploidies, sub-microscopic deletions and duplications detected by microarray, and uniparental disomy. Recognition of a chromosomal etiology reframes the diagnosis, provides recurrence risk information, and may identify additional health surveillance needs.
Key Points
- Chromosomal microarray diagnostic yield in CP: ~7–11% when applied to children with CP phenotype regardless of MRI findings; highest yield in term-born children with no perinatal risk factor and normal/non-diagnostic MRI
- 17p13.3 deletions (LIS1/PAFAH1B1, YWHAE): Miller-Dieker syndrome — pachygyria/lissencephaly on MRI; most severe neurological impairment; facial features
- 15q11-13 duplication/Prader-Willi/Angelman: Angelman syndrome can present as 'CP-like' with ataxic gait, absent speech, seizures — SNRPN methylation testing is important
- 1p36 deletion syndrome: hypotonia, moderate-severe intellectual disability, seizures, cardiomyopathy — can present as CP phenotype; specific distinctive features
- Xq28 MECP2 duplication: males with progressive spastic quadriplegia, severe intellectual disability, respiratory infections — clinically resembles CP; distinguished by progressive course and X-linked family history. Somatic mosaicism can also complicate CP phenotype interpretation (see the [[mosaicism|Mosaicism]] module)
✦ Check Your Understanding
A term-born child with moderate intellectual disability, absent speech, seizures, and a happy, social demeanor is initially labeled with CP. SNRPN methylation testing shows only the unmethylated (paternal) band present, with the methylated (maternal) band absent. This child most likely has:
Select an answer to reveal the explanation
Monogenic Causes and CP Mimics
Single-gene variants can produce phenotypes that meet clinical criteria for CP — motor impairment present from infancy in the context of an apparently non-progressive course. At least 10 monogenic conditions are commonly misdiagnosed as CP: DRD (GCH1), HSP (SPG4+), AHC (ATP1A3), leukodystrophies, Rett (MECP2), ARG1 deficiency, GA1 (GCDH), NPC, mitochondrial disease, and spinal cord pathology. A levodopa trial is MANDATORY in any child with dystonia and a normal MRI — DRD response is dramatic within days, low risk, and potentially life-changing. ARG1 deficiency presents as progressive spastic diplegia with elevated plasma arginine and is a treatable urea cycle disorder. Progressive or regressive course rules out CP by definition and demands urgent metabolic and genomic workup.
CP Mimickers — 10 Conditions to Know
| Disorder | Red Flag | Gene | Key Test |
|---|---|---|---|
| Dopa-responsive dystonia | Diurnal variation — worse PM, better AM | GCH1 | Levodopa trial (MANDATORY) |
| Hereditary spastic paraplegia | Progressive spastic diplegia; multi-generational “CP” | SPG4 + >80 genes | Gene panel / WES |
| Alternating hemiplegia of childhood | Episodic hemiplegia alternating sides; onset <18 mo | ATP1A3 | Gene sequencing |
| Leukodystrophies | Regression after plateau | Multiple | MRI white matter signal + WES |
| Rett syndrome | Regression 12–18 mo; hand stereotypies | MECP2 | MECP2 sequencing |
| Arginase deficiency | Progressive spastic diplegia; ID | ARG1 | Plasma arginine |
| Glutaric aciduria type 1 | Macrocephaly + striatal injury after crisis | GCDH | Urine organic acids; newborn screen |
| Niemann-Pick C | VSGP + ataxia + cognitive decline + HSM | NPC1/NPC2 | Oxysterols; filipin staining |
| Mitochondrial disease | Episodic decompensation; multi-system | Multiple | Lactate; Leigh pattern MRI |
| Spinal cord pathology | Progressive diplegia; bowel/bladder dysfunction | N/A | Spinal MRI |
Levodopa Trial Protocol: Start 1–2 mg/kg/day divided TID, titrate over 2–4 weeks. DRD response: dramatic within days. Low risk, potentially life-changing. MANDATORY in dystonia + normal MRI.
Red Flag Rule: If “CP” is progressive or regressive — STOP. It is not CP. Rethink the diagnosis with metabolic screen + WES/WGS.
Key Points
- DRD (GCH1): diurnal variation of dystonia (worse PM, better AM); normal MRI; levodopa trial MANDATORY — start 1-2 mg/kg/day TID, titrate over 2-4 weeks; dramatic response confirms diagnosis; low risk, potentially life-changing
- HSP (SPG4 and >80 genes): progressive spastic diplegia mimicking CP; thin corpus callosum; AD inheritance — multi-generational 'CP' families are HSP until proven otherwise
- AHC (ATP1A3): episodic hemiplegia alternating sides, onset <18 months; sleep resolves episodes; may develop fixed dystonia over time
- ARG1 (arginase deficiency): progressive spastic diplegia with elevated plasma arginine — treatable UCD with protein restriction; hyperammonemia may be absent or subtle; must check plasma amino acids in any 'progressive CP'
- GA1 (GCDH): macrocephaly + bilateral striatal injury after metabolic crisis; frontotemporal hypoplasia on MRI; identifiable on newborn screen; dietary lysine restriction prevents striatal crisis
✦ Check Your Understanding
Glutaric aciduria type 1 (GA1) can mimic CP. The mechanism of neurological injury in GA1 is:
Select an answer to reveal the explanation
Genetic Workup for Cerebral Palsy
The genetic investigation of CP has evolved from a karyotype-and-wait approach to a comprehensive tiered evaluation combining brain MRI, metabolic screening, chromosomal microarray, and exome sequencing. The yield of genetic testing is highest in term-born children without clear perinatal hypoxic-ischemic injury, children with normal or non-lesional MRI, and children with additional features (distinctive features, family history, regression, movement disorder beyond motor impairment).
Etiological Workup by Scenario
| Scenario | First-line Testing | Key Action |
|---|---|---|
| 1. All CP | Brain MRI | Identifies cause in ~80%. Normal MRI = RED FLAG — pursue genetic/metabolic workup |
| 2. Normal MRI / Unexplained | CMA + epilepsy panel or WES + metabolic screen | PAA, UOA, lactate, acylcarnitines |
| 3. Dyskinetic / Dystonic + Normal MRI | Levodopa trial + CSF neurotransmitters | GCH1/TH genes + plasma arginine |
| 4. Family Hx / Consanguinity / Distinctive Features | CMA → WES/WGS | Trio preferred for de novo detection |
| 5. Progressive / Regression | Metabolic screen + WES/WGS urgently | STOP — reconsider CP diagnosis |
Emerging: WGS as first-tier in some centers — detects SVs, repeat expansions, deep intronic variants; yield ~35–40%.
Key Points
- Tier 1: Brain MRI (3T if possible, with DWI and T2/FLAIR); evaluate for lesion pattern (PVL, cortical malformation, vascular, normal); metabolic panel (plasma amino acids, urine organic acids, lactate, ammonia, acylcarnitines); SNRPN methylation if Angelman features; levodopa trial if any diurnal fluctuation or dystonia
- Tier 2: Chromosomal microarray (SNP-based, for CNV and UPD); Fragile X if appropriate; specific targeted testing based on metabolic/clinical findings (e.g., GLUT1 if CSF:blood glucose low, SLC6A3 if parkinsonism-dystonia)
- Tier 3: Exome sequencing (trio analysis — patient + both parents preferred for de novo detection); highest yield ~25–30% in carefully selected patients with 'idiopathic CP'
- Features predicting high genetic yield: term birth, no HIE, normal MRI OR cortical malformation, family history of developmental delay/CP, additional features beyond motor (epilepsy, regression, movement disorder, distinctive features)
- Whole-genome sequencing: emerging as first-tier in some centers; detects SVs and deep intronic variants missed by exome; may screen for some short tandem repeat disorders; diagnostic yield ~35–40% in selected pediatric neurogenetics populations
✦ Check Your Understanding
Which clinical feature would most strongly support pursuing exome sequencing in a child labeled with CP?
Select an answer to reveal the explanation
Counseling and Management After Genetic Diagnosis
Identifying a genetic etiology in a child labeled with CP fundamentally changes the clinical trajectory — it provides a precise diagnosis, informs recurrence risk counseling for the family, directs surveillance for associated comorbidities, and increasingly identifies patients eligible for targeted therapies. Families should understand that a genetic diagnosis explains the cause without diminishing access to rehabilitation, educational, and therapeutic supports.
Treatment Reference
| Medication | Mechanism | Indication | Pearls |
|---|---|---|---|
| Oral Baclofen | GABA-B agonist | First-line spasticity | Titrate slowly; never stop abruptly (withdrawal risk) |
| Trihexyphenidyl | Anticholinergic | Dystonia | Titrate over weeks; watch cognitive & autonomic side effects |
| Levodopa | DA precursor | Mandatory DRD trial | 1–2 mg/kg/day TID; dramatic response = DRD confirmed |
| BoNT-A | NMJ blockade | Focal spasticity | Targeted muscles; repeat q3–6 mo; adjunct to therapy |
| ITB Pump | Intrathecal GABA-B | Severe; GMFCS III–V | Trial dose first; requires surgical implant & refills |
| SDR | Dorsal rhizotomy | Spastic diplegia GMFCS II–III | NOT for dystonia; requires intensive post-op PT |
⚠ Baclofen Withdrawal — EMERGENCY: Fever + altered mental status + rigidity + seizures + autonomic instability = baclofen withdrawal. Treat with IV benzodiazepines. If ITB pump — call neurosurgery STAT for pump interrogation.
Key Points
- Recurrence risk depends entirely on the genetic mechanism: de novo CNV or variant — <1% recurrence (germline mosaicism caveat); autosomal recessive — 25% per pregnancy; autosomal dominant variant inherited from affected parent — 50%; X-linked — depends on sex and carrier status
- Identifying treatable causes changes prognosis: DRD responds dramatically to levodopa; GLUT1 improves on ketogenic diet; AADC deficiency responds to gene therapy; GA1 can be prevented with dietary lysine restriction; biotinidase deficiency resolves with biotin
- Comorbidity surveillance by diagnosis: Down syndrome (thyroid, cardiac, sleep apnea); Angelman syndrome (epilepsy, scoliosis); MECP2 duplication (pulmonary hypertension, respiratory failure); SPG4 (urological symptoms, progressive course requiring active physiotherapy)
- The CP label does not preclude genetic investigation: some clinicians are reluctant to pursue genetics after CP diagnosis, believing etiology is established; evidence shows 20–30% of labeled CP cases have genetic causes that matter for management and family planning
- Variant of uncertain significance (VUS) counseling: ~20–30% of exome results yield VUS; distinguish VUS from pathogenic; review annually as databases grow; encourage research participation for data sharing
✦ Check Your Understanding
After exome sequencing, a child with CP phenotype is found to have a de novo pathogenic variant in KIF1A. The recurrence risk for the parents' next pregnancy is approximately:
Select an answer to reveal the explanation
0 of 5 sections read
Scroll through all sections to track your progress.